{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:31:37Z","timestamp":1770136297775,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.tox.2012.06.013","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T19:01:04Z","timestamp":1340910064000},"page":"33-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Evidence for nevirapine bioactivation in man: Searching for the first step in the mechanism of nevirapine toxicity"],"prefix":"10.1016","volume":"301","author":[{"given":"Umbelina","family":"Caixas","sequence":"first","affiliation":[]},{"given":"Alexandra M.M.","family":"Antunes","sequence":"additional","affiliation":[]},{"given":"Aline T.","family":"Marinho","sequence":"additional","affiliation":[]},{"given":"Ana L.A.","family":"Godinho","sequence":"additional","affiliation":[]},{"given":"N\u00e1dia M.","family":"Grilo","sequence":"additional","affiliation":[]},{"given":"M. Matilde","family":"Marques","sequence":"additional","affiliation":[]},{"given":"M. Concei\u00e7\u00e3o","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Branco","sequence":"additional","affiliation":[]},{"given":"Em\u00edlia C.","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"Sofia A.","family":"Pereira","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2012.06.013_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00019053-200018010-00002","article-title":"Economic issues in the prevention of vertical transmission of HIV","volume":"18","author":"Ades","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.tox.2012.06.013_bib0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijheh.2007.01.024","article-title":"Human biomonitoring: state of the art","volume":"210","author":"Angerer","year":"2007","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"10.1016\/j.tox.2012.06.013_bib0015","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/00002030-200108170-00018","article-title":"Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy","volume":"15","author":"Antinori","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.tox.2012.06.013_bib0020","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/tx8000972","article-title":"Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine","volume":"21","author":"Antunes","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2012.06.013_bib0025","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1021\/tx900443z","article-title":"Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine\u2014a possible factor in nevirapine toxicity","volume":"23","author":"Antunes","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2012.06.013_bib0030","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/tx100186t","article-title":"Protein adducts as prospective biomarkers of nevirapine toxicity","volume":"23","author":"Antunes","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2012.06.013_bib0035","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1086\/317536","article-title":"Sex differences in nevirapine rash","volume":"32","author":"Bersoff-Matcha","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tox.2012.06.013_bib0040","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-010611-134701","article-title":"Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex","volume":"52","author":"Bharadwaj","year":"2012","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.tox.2012.06.013_bib0045","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cbi.2006.10.005","article-title":"N-terminal globin adducts as biomarkers for formation of butadiene derived epoxides","volume":"166","author":"Boysen","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tox.2012.06.013_bib0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/pgs.11.132","article-title":"Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians","volume":"13","author":"Brown","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.tox.2012.06.013_bib0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1086\/520242","article-title":"Severe hepatic failure related to nevirapine treatment","volume":"29","author":"Cattelan","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tox.2012.06.013_bib0060","first-page":"1153","article-title":"Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997\u20132000","volume":"49","author":"Centers for Disease Control and Prevention (CDC)","year":"2001","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.tox.2012.06.013_bib0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FPC.0b013e32831d0faf","article-title":"HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients","volume":"19","author":"Chantarangsu","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.tox.2012.06.013_bib0070","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/tx800177k","article-title":"Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash","volume":"21","author":"Chen","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2012.06.013_bib0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.chroma.2007.07.044","article-title":"Analysis of hemoglobin adducts of acrylamide and glycidamide by liquid chromatography\u2013electrospray ionization tandem mass spectrometry, as exposure biomarkers in French population","volume":"1167","author":"Chevolleau","year":"2007","journal-title":"J. Chromatogr. A"},{"issue":"Suppl. 1","key":"10.1016\/j.tox.2012.06.013_bib0080","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1097\/00126334-200309011-00012","article-title":"Impact of nevirapine on lipid metabolism","volume":"34","author":"Clotet","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tox.2012.06.013_bib0085","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1468-1293.2008.00552.x","article-title":"Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts","volume":"9","author":"De Lazzari","year":"2008","journal-title":"HIV Med."},{"key":"10.1016\/j.tox.2012.06.013_bib0090","first-page":"118","article-title":"Immune dysfunction, inflammation, and accelerated\u00a0aging\u00a0in patients on antiretroviral therapy","volume":"17","author":"Deeks","year":"2009","journal-title":"Top. HIV Med."},{"key":"10.1016\/j.tox.2012.06.013_bib0095","first-page":"89","article-title":"FDA approves first new class of HIV drugs","volume":"11","author":"Food and Drug Administration","year":"1996","journal-title":"AIDS Alert"},{"key":"10.1016\/j.tox.2012.06.013_bib0100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1345\/aph.19258","article-title":"Frequency of cutaneous reactions on rechallenge with nevirapine and delavirdine","volume":"34","author":"Gangar","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.tox.2012.06.013_bib0105","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/QAD.0b013e32801199d9","article-title":"HLA-Cw8 primarily associated with hypersensitivity to nevirapine","volume":"21","author":"Gatanaga","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.tox.2012.06.013_bib0110","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1097\/00002030-199815000-00026","article-title":"High incidence of nevirapine-associated rash in HIV-infected Chinese","volume":"12","author":"Ho","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.tox.2012.06.013_bib0115","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1001\/jama.284.21.2722","article-title":"Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers","volume":"284","author":"Johnson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.tox.2012.06.013_bib0120","first-page":"237","article-title":"Use of carcinogen-DNA and carcinogen-protein adduct biomarkers for cohort selection and as modifiable end points in chemoprevention trials","volume":"139","author":"Kensler","year":"1996","journal-title":"IARC Sci. Publ."},{"key":"10.1016\/j.tox.2012.06.013_bib0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1742-6405-6-22","article-title":"HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients","volume":"6","author":"Likanonsakul","year":"2009","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.tox.2012.06.013_bib0130","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1097\/01.aids.0000238408.82947.09","article-title":"HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients","volume":"20","author":"Littera","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.tox.2012.06.013_bib0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa062876","article-title":"Response to antiretroviral therapy after a single, peripartum dose of nevirapine","volume":"356","author":"Lockman","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9308","key":"10.1016\/j.tox.2012.06.013_bib0140","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.tox.2012.06.013_bib0145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","article-title":"Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts","volume":"19","author":"Martin","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.tox.2012.06.013_bib0150","first-page":"110","article-title":"Risk for immune-mediated liver reactions by nevirapine revisited","volume":"10","author":"Medrano","year":"2008","journal-title":"AIDS Rev."},{"key":"10.1016\/j.tox.2012.06.013_bib0155","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1021\/tx990043x","article-title":"Characterization of the reactivity, regioselectivity, and stereoselectivity of the reactions of butadiene monoxide with valinamide and the N-terminal valine of mouse and rat hemoglobin","volume":"12","author":"Moll","year":"1999","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2012.06.013_bib0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.pharmtox.45.120403.100058","article-title":"The role of metabolic activation in drug-induced hepatotoxicity","volume":"45","author":"Park","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.tox.2012.06.013_bib0165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cbi.2010.09.011","article-title":"Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity","volume":"192","author":"Park","year":"2011","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tox.2012.06.013_bib0170","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00126334-200402010-00003","article-title":"Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals","volume":"35","author":"Patel","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tox.2012.06.013_bib0175","isbn-type":"print","article-title":"Understanding the molecular basis for the hazards associated with nevirapine treatment","volume":"vol. 44","author":"Pereira","year":"2012","ISBN":"https:\/\/id.crossref.org\/isbn\/9781621009610"},{"key":"10.1016\/j.tox.2012.06.013_bib0180","series-title":"Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States","author":"Perinatal HIV Guidelines Working Group","year":"2009"},{"key":"10.1016\/j.tox.2012.06.013_bib0185","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00130832-200108000-00006","article-title":"HIV and drug allergy","volume":"1","author":"Pirmohamed","year":"2001","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.tox.2012.06.013_bib0190","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2008.19.6626","article-title":"Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection","volume":"27","author":"Powles","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tox.2012.06.013_bib0195","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/mas.20207","article-title":"Toward an \u201comic\u201d physiopathology of reactive chemicals: thirty years of mass spectrometric study of the protein adducts with endogenous and xenobiotic compounds","volume":"28","author":"Rubino","year":"2009","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.tox.2012.06.013_bib0200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00042560-200107010-00003","article-title":"Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study","volume":"27","author":"Ruiz","year":"2001","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tox.2012.06.013_bib0205","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2174\/092986709788803097","article-title":"Current concepts of mechanisms in drug-induced hepatotoxicity","volume":"16","author":"Russmann","year":"2009","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tox.2012.06.013_bib0210","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/tx034064+","article-title":"Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat","volume":"16","author":"Shenton","year":"2003","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2012.06.013_bib0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/03602539409029787","article-title":"Protein adducts as biomarkers of human carcinogen exposure","volume":"26","author":"Skipper","year":"1994","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.tox.2012.06.013_bib0220","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1124\/dmd.109.028688","article-title":"Quantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometries","volume":"38","author":"Srivastava","year":"2010","journal-title":"Drug Metab. Dispos."},{"issue":"Suppl 1","key":"10.1016\/j.tox.2012.06.013_bib0225","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00126334-200309011-00005","article-title":"A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients","volume":"34","author":"Stern","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tox.2012.06.013_bib0230","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication","volume":"13","author":"St\u00f6hr","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.tox.2012.06.013_bib0235","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1258\/095646206777323346","article-title":"Nevirapine toxicity","volume":"17","author":"Taiwo","year":"2006","journal-title":"Int. J. STD AIDS"},{"key":"10.1016\/j.tox.2012.06.013_bib0240","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.2010.1004","article-title":"Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel","volume":"304","author":"Thompson","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.tox.2012.06.013_bib0245","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1570-0232(02)00172-1","article-title":"Protein adducts: quantitative and qualitative aspects of their formation, analysis and application","volume":"778","author":"T\u00f6rnqvist","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.tox.2012.06.013_bib0250","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0753-3322(03)00043-X","article-title":"The importance of glutathione in human disease","volume":"57","author":"Townsend","year":"2003","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tox.2012.06.013_bib0255","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAD.0b013e3282f37812","article-title":"HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz","volume":"22","author":"Vitezica","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.tox.2012.06.013_bib0260","first-page":"143","article-title":"Carcinogen-DNA and carcinogen-protein adducts in molecular epidemiology","volume":"142","author":"Wild","year":"1997","journal-title":"IARC Sci. Publ."},{"key":"10.1016\/j.tox.2012.06.013_bib0265","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":"Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients","volume":"61","author":"Wyen","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tox.2012.06.013_bib0270","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1097\/QAD.0b013e32834779df","article-title":"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent","volume":"25","author":"Yuan","year":"2011","journal-title":"AIDS"}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X12002430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X12002430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:21:47Z","timestamp":1759533707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X12002430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":54,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0300483X12002430"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2012.06.013","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for nevirapine bioactivation in man: Searching for the first step in the mechanism of nevirapine toxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2012.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}